Jason Stahl
Ophthalmology · Overland Park, KSNPI 1205830627
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,000 of the $9,981 with a category attached, or 90.2%. Rxsight Inc accounts for 90.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $9,197 and has fallen 99.7% since, to $26 in 2024. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $433.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$9K
- Alcon$703
- Johnson & Johnson Surgical Vision, Inc.$125
- The Cameron-ehlen Group, Inc.$41
- Novartis$24
- Oyster Point Pharma, Inc.$21
- plus $41 from 3 others
Across 199 payments — averaging $2412.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$175K
- Oyster Point Pharma, Inc.$166K
- Bausch Health US, LLC$87K
- Rxsight Inc$51K
- Johnson & Johnson Surgical Vision, Inc.$2K
What the payments were for
- Consulting fees$9,00090%
- Speaking & faculty fees$260%
- Travel & lodging$120%
- Food & beverage$9439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 2 | $9,026 |
| Alcon | 14 | $703 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| The Cameron-ehlen Group, Inc. | 1 | $41 |
| Novartis | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Carl Zeiss Meditec, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,981 in reported general payments places this provider in the 90th percentile of 135 ophthalmology providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 29 | $10,633 |
| Prednisolone Acetate | 103 | $2,336 |
| MoxifloxacinMoxifloxacin Hcl | 82 | $1,783 |
| Ketorolac Tromethamine | 47 | $618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $24 | $10,63329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Overland Park
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Christopher KetchersideOverland Park$6K
- Selena FuOverland Park$5K
- Timothy CavanaughOverland Park$5K
- Johann OhlyOverland Park$4K
- Keith WarrenOverland Park$4K
- Austin AndersenOverland Park$3K
- Kristin Schmid BiggerstaffOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.